RAP 0.00% 20.5¢ resapp health limited

Ann: Positive Results for Australian Prospective Paediatric Study, page-148

  1. 2,702 Posts.
    lightbulb Created with Sketch. 504
    Well understood regulatory pathway
    - Held US FDA Pre-Submission meeting in Q1 CY2016, confirmed de novo regulatory pathway strategy
    - FDA submission following US pediatric study completion
    - CE (Europe) and TGA (Australia) submissions following Australian prospective study completion

    That’s Mr Genius to you.....your argument was sorted our back in Q1 2016.
 
watchlist Created with Sketch. Add RAP (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.